Skip to main content
. Author manuscript; available in PMC: 2011 Dec 3.
Published in final edited form as: J Allergy Clin Immunol. 2011 Jul 26;128(6):1259–1265.e2. doi: 10.1016/j.jaci.2011.06.015

Fig 1. Suppression of allergen stimulated basophil activation by FAHF-2 in a six month phase-I clinical study.

Fig 1

Patients’ blood pre-treatment (0 month) and at consecutive 2 month time-points during a six month clinical phase-I study for FAHF-2 was stimulated with increasing doses of allergen in the presence of stimulation buffer. Percent CD63 for A) 200ng/mL, B) 200pg/mL and C) 0.2pg/mL of allergen are shown.*, p<0.05; **, p<0.01. Each symbol represents individual patient and bar is the median from each group.